Epidemiology of multiple myeloma in city Moscow


Cite item

Full Text

Abstract

Aim. To study the epidemiology of multiple myeloma in the city of Moscow and compare the results obtained with data from similar studies in other countries. Materials and methods. The study is based on information from a database of case histories of 3942 patients suffering from symptomatic MM, residents of the city of Moscow, which is maintained at the Hematologic Moscow City Center of S.P. Botkin Municipal Clinical Hospital. The control of the completeness of inclusion was carried out by cross - comparison with the data of the Moscow Cancer Register and the Register of Program 7 (beginning in 2019 - 12) of Highly Expensive Nosologies. The assessment was made according to data as of January 1, 2019. The calculations were carried out taking into account the data of Rosstat at the beginning of 2019 on the population of Moscow in different gender and age categories. Results. Among the 3942 patients with active MM 1707 men - 43% and 2241 women - 57%, the median of the current age was 68 (28-94) years. The median time of observation of patients since the diagnosis of the disease 34 (1-423) months. The peak incidence was in the age range of more than 60 years. There were no significant differences in gender ratio in different age strata with a breakdown of 10 years. The number of cases of newly diagnosed MM per year for the period from 2009 (n=219) to 2018 (n=385) increased by 75.8%. At the same time, the demonstrated increase in the incidence rate for the described period turned out to be fair only for groups of patients over 50 years old, with the maximum increase in this indicator over the described period in the age range of 60-69 years. This is mainly due to the increase in life expectancy in Moscow in recent years. The study demonstrated that over the past 10 years, the average annual mortality rate from MM has decreased in Moscow, and as a result, its prevalence has increased. The rate of 2-year overall survival of patients with MM was 76%, 5-year - old - 49%, 10-year - old - 27%. The median overall survival of patients under the age of 65 when diagnosing the disease was 79 months, and 48 months. The distribution of patients within international classifications was consistent with international data. Conclusions. The study revealed a significant dynamic of the epidemiological situation concerning MM in Moscow. Over the past 10 years there has been an increase in the incidence of MM, as a result of an increase in the life expectancy of the population. The use of modern diagnostics and therapy of MM in real clinical practice has led to a significant reduction in mortality. Due to these factors, an increase in the prevalence of MM in Moscow has taken place, and this process will no doubt progress in the future.

About the authors

O Yu Vinogradova

Botkinsky hospital; Dmitry Rogachev National Research of pediatric hematology/oncology and immunology; Pirogov Russian National Research Medical University

д.м.н., проф., зав. Московским городским гематологическим центром ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ; проф. каф. гематологии, онкологии и лучевой терапии ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ORCID: 0000-0002-3669-0141 Moscow, Russia

V V Ptushkin

Botkinsky hospital; Dmitry Rogachev National Research of pediatric hematology/oncology and immunology; Pirogov Russian National Research Medical University

проф., зам. главного врача по гематологии ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ; проф. каф. гематологии, онкологии и лучевой терапии ПФ ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; главный внештатный гематолог Департамента здравоохранения города Москвы; ORCID: 0000-0002-9368-6050 Moscow, Russia

M V Chernikov

Research Institute of health care organization and medical management

программист ОМО по гематологии ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» ДЗМ; ORCID: 0000-0002-7869-209X Moscow, Russia

Yu B Kochkareva

Botkinsky hospital

Email: kochkareva_yulia@mail.ru
к.м.н., врач-гематолог клинико-гематологического отд-ния Московского городского гематологического центра ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ; ORCID: 0000-0003-1583-8298 Moscow, Russia

V A Zherebtsova

Botkinsky hospital

врач-гематолог гематологического отд-ния ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ; ORCID: 0000-0002-3052-269Х Moscow, Russia

References

  1. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25-35. doi: 10.1007/978-3-540-85772-3_2
  2. Benjamin M, Reddy S, Brawley O.W. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 2003 Mar;22(1):87-93.
  3. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016 Dec;43(6):676-81. doi: 10.1053/j.semin oncol.2016.11.004. Epub 2016 Nov 10
  4. Bethesda M.D. SEER Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity: Both Sexes, 18 SEER Areas, 2012-2014 (Table 1.15) National Cancer Institute, Accessed at https://seer.cancer.gov/csr/1975_2014/results_merged/topic_lifetime_risk.pdf on January 5, 2018
  5. Cowan A.J, Allen C, Barac A. Global Burden of Multiple Myeloma. A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221-7. doi: 10,1001/jamaoncol.2018.2128
  6. Luciano J. Costa, Jim Omel and Elizabeth E. Brown. Recent Trends in Multiple Myeloma Incidence and Survival By Age, Race and Ethnicity in the US. Blood. 2016 Dec;128(22):4774.
  7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac. 20006. Epub 2009 May 27.
  8. Multiple myeloma epidemiology and demographics Editor-In-Chief: C. Michael Gibson, M.S, MD. Associate Editor(s)-in-Chief: Haytham Allaham, MD. 2018.
  9. Hong J, Lee J.H. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med. 2016;31(5):820-34. doi: 10.3904/kjim.20 15.408. Epub 2016 Sep 1.
  10. American Cancer Society Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html
  11. Raluy M, Ramagopalan S, Panjabi S and Lambrelli D. Epidemiology and Clinical Characteristics of Patients with Multiple Myeloma in the United Kingdom. Blood. 2014;124:2048.
  12. Blimark C.H, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist U.H, Nahi H, Kristinsson S.Y. Swedish Myeloma Registry. Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR). Haematologica. 2018 Mar;103(3):506-13. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.
  13. Jump up↑ Plasma cell neoplasm. National cancer institute (2015). http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#cit/section_1.1 Accessed on September, 20th 2015
  14. Seer stat fact sheet. National cancer institute (2015) http://seer.cancer.gov/statfacts/html/mulmy.html Accessed on September, 20th 2015
  15. Myeloma - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/ mulmy.html
  16. A snapshot of myeloma. National cancer institute (2014). http://www.cancer.gov/research/progress/snapshots/myeloma Accessed on September, 20th 2015
  17. Solovev M, Mendeleeva L, Pokrovskaya O, Gemdzhian E, Volodicheva E, Anchukova L, Menshakova S, Osyunikhina S, Voytsekhovski V, Savchenko V. Epidemiology and Clinical Characteristics of Patients with Multiple Myeloma. Results of a Prospective Multicenter Study in Russian Federation. Blood. 2015;126:4248.
  18. Бутуханова И.С., Жалсанова Э.Б., Алексеева А.Н., Очирова О.Е. Анализ заболеваемости множественной миеломой в республике Бурятия. Современные проблемы науки и образования. 2016;(4). URL: http://www.science-education.ru/ru/article/view?id=24818
  19. Лучинин А.С., Семочкин С.В., Минаева Н.В., Поздеев Н.М, Парамонов И.В. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50-6. https://doi.org/10.17650/ 1818-8346-2017-12-3-50-56
  20. Менделеева Л.П., Вотякова О.М., Покровская О.С., Рехтина И.Г., Дарская Е.И., Гальцева И.В., Капланов К.Д., Моторин Д.В., Самойлова О.С., Семочкин С.В., Скворцова Н.В., Соловьев М.В., Урнова Е.С., Савченко В.Г. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;61(1,Прил.2):1-24. doi: 10.18821/0234-5730-2016-61-1
  21. Durie B.G.M, Salmon S.E. A clinical staging system for multiple myeloma: Correlation of measure Myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36 (9):842-54.
  22. Greipp P.R, San Miguel J.F, Durie B.G, et al. International Staging System for Multiple Myeloma. J Clin Oncol. 2005;23(15):3412-20.
  23. Численность населения Российской Федерации по муниципальным образованиям. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/publications/catalog/afc8ea004d56a39ab251f2bafc3a6fce

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies